BioCentury
ARTICLE | Finance

Italy’s Panakès now targeting therapeutics with second fund

€150M first close adds firepower in country underserved by VC

July 20, 2021 10:28 PM UTC

Panakès’ experience investing its first fund in medtech companies has led the Italian firm to branch into therapeutics for its Purple Fund, a new vehicle that has completed a first close at €150 million.

The firm’s Diana Saraceni told BioCentury some investments from Panakès Partners’ first fund stemmed from a “therapeutic angle” and were geared to “change the prognosis of a certain patient population,” although they did fall into the firm’s original areas of expertise: medical devices, diagnostics and digital health...